Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma

BMC Veterinary Research

Table 3 Factors evaluated by univariate analysis for association with progression free survival (PFS) and overall survival (OS)

		n	Median PFS (days)	p-value	HR (95% CI)	Median OS (days)	p-value	HR (95% CI)
Substage	a	24	147	0.72	1.16 (0.491 to 2.92)	227	0.76	0.89 (0.379 to 2.00)
Substage	b	9	134	0.72	1.16 (0.491 to 2.92)	148	0.76	0.89 (0.379 to 2.00)
L-asparaginase at Induction	No	12	147	0.9	0.95 (0.417 to 2.15)	245	0.89	0.95 (0.458 to 1.96)
L-asparaginase at Induction	Yes	21	147	0.9	0.95 (0.417 to 2.15)	152	0.89	0.95 (0.458 to 1.96)
Thrombocytopenia	No	22	147	0.18	0.59 (0.210 to 1.30)	198	0.79	0.91 (0.416 to 1.95)
Thrombocytopenia	Yes	11	127	0.18	0.59 (0.210 to 1.30)	148	0.79	0.91 (0.416 to 1.95)
Body weight	< 15 kg	8	147	0.57	0.76 (0.302 to 1.89)	138	0.63	1.219 (0.530 to 2.90)
Body weight	> 15 kg	25	147	0.57	0.76 (0.302 to 1.89)	198	0.63	1.219 (0.530 to 2.90)
Anemia	No	7	139	0.55	1.33 (0.540 to 3.35)	152	0.83	0.915 (0.382 to 2.17)
Anemia	Yes	26	177	0.55	1.33 (0.540 to 3.35)	227	0.83	0.915 (0.382 to 2.17)
Protocol Completion	No	18	61	< 0.0001	5.66 (17.3 to 324)	101	< 0.0001	4.59 (7.15 to 55.3)
Protocol Completion	Yes	15	170	< 0.0001	5.66 (17.3 to 324)	291	< 0.0001	4.59 (7.15 to 55.3)
Protocol Duration	5 tx	15	162	0.83	1.12 (0.384 to 3.38)	308	0.87	0.91 (0.289 to 2.83)
Protocol Duration	6 tx	4	185	0.83	1.12 (0.384 to 3.38)	226	0.87	0.91 (0.289 to 2.83)
Rescue Chemotherapy	No	13	–	–	–	148	0.013	2.35 (1.36–7.30)
Rescue Chemotherapy	Yes	15	–	–	–	325	0.013	2.35 (1.36–7.30)

ISSN: 1746-6148